ICON
ICON is a clinical research organisation (CRO) which provides outsourced development services on a global basis to the pharmaceutical, biotechnology and medical device industries. The company’s mission is to accelerate the development of drugs and devices that save lives and improve the quality of life. ICON specialises in the strategic development, management and analysis of programmes to support all stages of the of the clinical development process.
Website besuchen- Unternehmenswert
- US$20.4 bn
- Region
- Ireland
- Thema
- Health
- Unterthema
- Research and diagnostics
Impact-Bewertung
ICON’s services result in reduced time and cost in clinical trials. However, their clients in the pharmaceutical and biotech sectors are already well-served and the impact generated is incremental as these processes would otherwise be performed in-house.
Fundamentale Qualität
ICON is one of a select group of Contract Research Organisations with the expertise and capability to conduct clinical trials in most major therapeutic areas on a global basis. The company also has a strong management team with a high quality management system that ensures all services meet the highest ethical standards.
UN-Nachhaltigkeitsziele
By providing contract research services ICON directly supports the development of new therapies and supports the achievement of SDG3.
Mehr erfahrenRisiko negativer Auswirkungen
- Clinical trials produce a large amount of medical waste including plastics and toxic chemicals
- Clinical trials pose a risk of adverse events to trial participants
Verwandte Einblicke Verwandte Inhalte
Sustainable
The next constraint on AI is not just energy, it's also water
Von Ty Lee
10. März 2026 | 3 min read
Sustainable
From villain to saviour – renewable energy is coming to the rescue
Von WHEB Investment Team
17. Feb. 2026 | 6 min read
Sustainable
Are EVs really rolling backwards?
Von WHEB Investment Team
19. Jan. 2026 | 5 min read
Sustainable
Sustainable investment trends for 2026
Von Seb Beloe
19. Jan. 2026 | 5 min read